Building on this foundation, our current research focuses on combining the STING agonist c‐di‐AMP with ginsenoside Rg3 to evaluate their combined impact on cisplatin‐resistant gastric cancer cells (SGC‐7901/DDP). The gene discussed is STING1; the disease is gastric cancer.